Jay Evans
Chief Scientific and Strategy Officer
Inimmune
Inimmune develops novel immunotherapeutics utilizing Toll-like receptor (TLR) agonists to enhance immune responses in cancer and allergy treatments. Their clinical-stage assets, including INI-2004 and INI-4001, aim to provide disease-modifying effects for allergic rhinitis and cancer, addressing the need for more effective immunotherapy options.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$22MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current cancer and allergy treatments often fail to elicit a sufficient immune response, limiting their effectiveness in modifying disease progression. Traditional vaccine adjuvants may also lack the potency or specificity needed to generate robust and targeted immunity.
Solution
Inimmune is developing immunotherapeutics and vaccine adjuvants based on Toll-like receptor (TLR) agonists to enhance and modulate immune responses. Their clinical-stage assets, INI-2004 (TLR4 agonist) and INI-4001 (TLR7/8 agonist), are designed to provide disease-modifying effects for allergic rhinitis and cancer, respectively. Inimmune's pipeline also includes preclinical programs focused on next-generation vaccine adjuvants and novel innate immune agonists and antagonists. These therapies aim to improve treatment outcomes by stimulating the innate immune system and promoting a more effective adaptive immune response.
Target Audience
The primary target audience includes patients with cancer and allergic diseases, as well as pharmaceutical companies and research institutions seeking advanced vaccine adjuvants and immunotherapeutic agents.
Features
- INI-2004: A TLR4 agonist in Phase 1 clinical trials for the treatment of allergic rhinitis, administered intranasally.
- INI-4001: A TLR7/8 agonist in Phase 1 clinical trials as a cancer treatment, both as a monotherapy and in combination with checkpoint inhibitors.
- Development of novel combination adjuvants in collaboration with the University of Chicago.
- Opioid vaccine development project in collaboration with the University of Washington and Columbia University.
- Sublingual food allergy therapy development in collaboration with the University of North Carolina and Duke University, combining INI-2004 with Intrommune’s oral mucosal immunotherapy.
- Universal influenza vaccine development project in collaboration with Cleveland Clinic.
- STING adjuvant discovery project in collaboration with OHSU.